Zamur

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zamur

Property Description
Active ingredient Cefuroxime
Form Tablets, Oral Suspension, Powder for Injection Solution
Pharmacological class beta-Lactam Antibiotic (Second-generation Cephalosporin)
General purpose Eradication of bacterial infections
Origin Semi-synthetic

Defining Zamur: Class, Composition, and Forms

Zamur is a specific, commercially available brand of medicine containing the active ingredient Cefuroxime, which is classified as a prescription-only medicine and an antibiotic utilized for resolving bacterial infections. Cefuroxime is a semi-synthetic compound placed within the Second-generation cephalosporin group, which itself belongs to the broader beta-Lactam antibiotic class. Pharmacologically, cephalosporins are distinguished by their structure and mechanism of action against susceptible bacteria. The active ingredient is available in several pharmaceutical preparations to allow for different routes of administration, including film-coated tablets and oral suspension for oral intake, or as a sterile powder for injection solution for parenteral delivery.

The General Purpose of Cefuroxime

The core objective of Cefuroxime is to function as an anti-infective agent for the definitive elimination of susceptible bacterial infections. The drug is designed as a potent bactericidal agent, meaning it actively kills the target microorganisms rather than merely inhibiting their growth. This action is crucial for clearing infections, and the mechanism involves inhibition of bacterial cell wall synthesis, a critical physiological action that prevents the microbes from maintaining structural integrity. A key advantage of this agent is its structural ability to confer significant resistance to beta-lactamases—enzymes frequently produced by bacteria to neutralize older antibiotics. This enhanced stability allows Cefuroxime to maintain its efficacy and provide broad-spectrum activity against various pathogens during common systemic infections, such as those affecting the respiratory tract.

What side effects are possible with Zamur?

Zamur (Cefuroxime): Possible Side Effects and Safety Information

Zamur's safety profile is documented by regulatory agencies and classified by frequency and affected body systems. The most Common adverse reactions (occurring in ge 1/100 to <1/10 patients) listed in official labeling include eosinophilia, neutropenia, headache, dizziness, diarrhea, and transient increases in liver enzymes.

Uncommon effects (ge 1/1,000 to <1/100) may involve leucopenia, decreased hemoglobin concentration, and a positive Coombs' test, alongside skin reactions like rash and urticaria.

Several serious adverse reactions are documented, though they are classified as rare or very rare. These include severe hypersensitivity events such as anaphylaxis and life-threatening skin conditions like Stevens-Johnson Syndrome. The use of Cefuroxime is associated with the risk of Clostridioides difficile-associated diarrhea (CDAD), which can occur up to two months after treatment ceases.

Safety Constraints and Considerations:

  • Hypersensitivity: The medicine is contraindicated in patients with a known allergy to Cefuroxime or other beta-lactam antibiotics.
  • Microbial Overgrowth: There is potential for the overgrowth of non-susceptible organisms, such as Candida.
  • Renal Function: Specific safety notes indicate that slower drug clearance in patients with impaired renal function may increase the risk of systemic effects.
  • Diagnostic Interference: The drug may cause false-positive results in certain urine glucose tests and a positive Coombs' test.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Zamur (Cefuroxime) overdose centers on manifestations of Central Nervous System (CNS) excitability. Documented presentations include signs of cerebral irritation, convulsions (seizures), and other neurological sequelae. In severe cases, overdose may progress to serious outcomes such as encephalopathy and coma.

A critical element in the overdose profile is the regulatory warning that the risk of toxicity is elevated in individuals with impaired renal function. Overdose symptoms may manifest if the dose is not appropriately adjusted for reduced kidney function, requiring careful observation.

In the event of a suspected overdose, the first regulatory action is immediate discontinuation of the medicine. Urgent medical attention is required. Patients or caregivers must seek immediate medical attention or call emergency services if severe symptoms, such as collapse, seizure, or inability to be awakened, are present.

Management focuses on symptomatic and supportive treatment. No specific antidote is known, but procedures to enhance drug clearance, such as haemodialysis, may be considered in cases of severe overdose or renal impairment. Close monitoring for CNS toxicity is necessary.

Therapeutic Uses of Zamur

Zamur (Cefuroxime) is commonly used to help manage acute bacterial infections across several major therapeutic domains, supporting patients during difficult episodes by easing distress. Cefuroxime is an antibiotic prescribed for various infections caused by bacteria, including infections of the respiratory tract, skin, and urinary system.


Therapeutic Scope and Symptom Relief

The medication is considered relevant in contexts where additional symptomatic support is appropriate across several domains. It may be part of symptomatic management for conditions such as bacterial pharyngitis, tonsillitis, acute otitis media, sinusitis, pneumonia, uncomplicated skin infections, and urinary tract infections (UTIs). The therapy offers symptomatic relief that may help patients during episodes of heightened discomfort. Zamur may be part of symptomatic management in certain severe conditions, which can include septicemia, meningitis, bone and joint infections, and the early stages of Lyme disease.

It is used to address symptom clusters like fever, severe localized pain, and inflammation. Zamur supports patients during episodes of heightened discomfort by easing symptoms that create noticeable physiological strain and interfere with daily functioning.

Quick Fact: Relief for Inflammatory Discomfort

Zamur is commonly used in situations involving symptoms related to inflammatory or irritative states. It assists with maintaining functional stability by supporting a reduction in symptoms that create noticeble physiological strain and interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Zamur?

The population eligibility for using Zamur (Cefuroxime) is strictly defined by regulatory authorities based on absolute contraindications and conditional restrictions.

Absolute Non-Eligibility

Use of this medicine is contraindicated in patients with a known hypersensitivity to Cefuroxime or to any other beta-Lactam antibacterial agent, including penicillins or other cephalosporins. This prohibition is based on the risk of severe allergic reactions.


Conditional and Restricted Use

Population Group Eligibility Status (Regulatory Wording)
Age (Pediatric) Use is not established in infants younger than 3 months for the oral suspension.
Renal Function Patients with markedly impaired renal function require conditional use; dosage adjustment is necessary.
Pregnancy/Lactation Conditional eligibility; use is permitted only if the benefit outweighs the risk due to limited data.
Comorbidity The oral suspension is restricted for patients with Phenylketonuria (PKU) due to the presence of phenylalanine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Zamur (Cefuroxime) is defined by documented effects on the drug's exposure and its influence on other co-administered substances, as stated in regulatory prescribing information. No specific drug-drug combinations are formally classified as contraindications due to interaction risk.

Official Interaction Statements

Category Interacting Substance Official Regulatory Outcome
Pharmacokinetic Probenecid Documented to increase Cefuroxime systemic exposure (AUC) and prolong its half-life by inhibiting renal tubular secretion.
Pharmacokinetic Gastric Acidity Reducers (e.g., Antacids, PPIs) Reduces the bioavailability of the oral form (Cefuroxime axetil).
Pharmacodynamic Oral Anticoagulants Concomitant use may increase the International Normalised Ratio (INR), reflecting a change in coagulation parameters.

Administration-Related Constraints

The interaction with substances that reduce gastric acidity necessitates a timing separation rule: administration of antacids must be separated by at least one hour before or two hours after the oral Cefuroxime. The absorption of the oral form is officially enhanced by food. Furthermore, caution is advised when Cefuroxime is co-administered with nephrotoxic preparations or strong diuretics (e.g., Furosemide), particularly in patients with impaired renal function, due to a documented risk of potential functional impairment.

Mechanism of Action

Targeted Disruption of Bacterial Cell Wall Structure

Zamur's mechanism begins at the molecular level with the targeted inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes necessary for forming the structural mesh of the cell wall (peptidoglycan). By covalently binding to and inactivating these enzymes, the drug effectively blocks the final cross-linking step of wall assembly, leading to a loss of microbial structural integrity. This action causes the bacterial cell to lyse (rupture) due to osmotic pressure, resulting in a rapid bactericidal effect against target microbial populations.

Intrinsic Stability and Mechanistic Evasion

The structural design of Cefuroxime confers stability against many forms of bacterial defense enzymes known as beta-lactamases. These enzymes typically hydrolyze and inactivate beta-lactam antibiotics. By being a poor substrate for these common inactivating enzymes, Zamur allows its molecular mechanism to remain intact and engage the target PBPs. This stability supports the physiological consequence of reduced pathogen count, though the mechanism can be constrained by specific enzyme variants or by altered PBP targets.

Dosage and Administration Information

How to Use Zamur (Cefuroxime) — Administration Guidelines

Zamur, containing the active ingredient Cefuroxime, is administered via two approved routes depending on the pharmaceutical form: oral for Cefuroxime Axetil (tablets and suspension) and parenteral (IV or IM) for Cefuroxime Sodium (injection). The method and frequency of use are strictly defined for each preparation.


Dosage and Frequency

Zamur is typically prescribed twice daily (every 12 hours) for oral forms and three times daily (every 8 hours) for parenteral forms. The typical duration of treatment is 5 to 10 days, although therapy for early Lyme disease is typically 20 days (oral). The following table outlines standard adult regimens:

Administration Route Standard Adult Dose Frequency Max Daily Dose (Severe)
Oral (Tablets/Suspension) 250 mg to 500 mg Every 12 hours 1,000 mg (single dose for gonorrhea)
Parenteral (IV/IM) 750 mg to 1.5 g Every 8 hours Up to 9 g IV (for meningitis)

Administration Requirements and Adjustments

Oral forms have specific intake instructions. The oral suspension must be taken with food for optimal absorption, while tablets can be taken with or without food. Tablets must be swallowed whole, as crushing is not permitted. The suspension and tablets are not interchangeable on a milligram-for-milligram basis due to differing absorption profiles.

For parenteral forms, deep intramuscular injection must not exceed 750 mg at a single site. Intravenous administration should be over 3 to 5 minutes (bolus) or 30 to 60 minutes (infusion).

Dose adjustment is required for patients with impaired renal function, with specific reductions prescribed based on the patient's creatinine clearance to compensate for the medicine's slower excretion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zamur (Cefuroxime)


Evidence for Acute Bacterial Infections of the Ear and Respiratory System

Research examined the medicine containing Cefuroxime for its use in conditions like acute otitis media (middle ear infection) and lower respiratory tract infections, which includes conditions such as pneumonia. The primary research design used were Randomized Controlled Trials (RCTs). Studies were applied in research contexts involving fluctuating or unstable symptoms, with researchers exploring outcomes related to physical discomfort and systemic or functional imbalance.

For acute otitis media, studies explored different treatment durations. Studies reported patterns related to clinical observations and microbiological change outcomes over short periods. However, the available research provides limited information for long-term outcomes (e.g., outcomes tracked beyond one year) and is not fully established.

For lower respiratory tract infections, studies monitored clinical and microbiological response using both oral and injectable forms. Research highlights changes measured during the study period, and data show patterns related to resistance in certain pathogens, which was a subject of the studies. Furthermore, specialized pharmacokinetic studies investigated therapeutic targets in specific patient groups, and research suggests these studies may explore non-standard drug exposure goals in severe cases.


Evidence for Skin, Urinary, and Vector-borne Infections

Research has also explored the evaluation of Zamur for complicated urinary tract infections (cUTIs), skin and soft tissue infections (SSTIs), and the early stage of Lyme disease.

For cUTIs, the research utilized both RCTs and retrospective observational studies. Outcomes measured included clinical resolution, microbiological findings related to urine culture, and research explored patterns related to recurrence over defined time intervals, with some follow-up durations extending for up to 30 months.

For early Lyme disease, the evidence is primarily derived from Randomized Studies. These trials explored short-term symptom changes and monitored clinical outcomes related to the observations related to the characteristic rash, Erythema Migrans, and the monitoring of later-stage signs.


Understanding Research Gaps and Uncertainty

Evidence highlights what is still uncertain across several areas:

  • Subgroup findings are uncertain in some populations.
  • Long-term effects are not fully established for most conditions.
  • Evidence quality varies across studies, with some indications relying on established literature or older controlled studies rather than recent, large-scale RCTs.

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Cefuroxime Drug Overview and Uses - MedlinePlus (NIH)
  2. Antibiotics for acute otitis media in children: A systematic review and meta-analysis [Cochrane Review supporting AOM data]

Frequently Asked Questions (FAQ)

Common questions about Zamur (FAQ)


Q: What happens if I miss a scheduled time to take Zamur?

If a dose is missed, official product information suggests that the dose be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, skip the missed dose entirely and take only the next scheduled dose. Taking a double dose to make up for a missed one is generally not advised by official guidelines.


Q: Is Zamur safe for people who have liver problems?

Regulatory information indicates that Zamur (Cefuroxime) is primarily eliminated from the body by the kidneys, not the liver. Therefore, dose adjustment is generally not necessary for patients who have hepatic (liver) impairment. Information regarding any specific conditions related to liver function is best addressed by a healthcare provider.


Q: Can Zamur be used during pregnancy or while breastfeeding? (Descriptive inquiry)

Official documents state that the medicine passes into breast milk. Use during pregnancy or while breastfeeding is only considered when the determined benefit is believed to outweigh the potential risk. This assessment requires professional evaluation and is based on limited available data.


Q: Are there any known issues with Zamur and birth control pills?

Regulatory prescribing information indicates that Zamur may reduce the effectiveness of certain hormonal contraceptives, such as birth control pills. Due to this potential interaction, regulatory documents suggest that the need for alternate or additional contraception should be evaluated during the period of treatment.

--רת

Q: Does Zamur interact with supplements like St. John's Wort or Omega-3?

Warnings published by regulatory bodies indicate that St. John’s Wort may interact with various medicines by affecting how the body breaks them down. Specific interactions with supplements like Omega-3 are not typically listed in the main interaction profiles.


Q: Can Zamur cause difficulty sleeping, and if so, how common is it?

Difficulty sleeping (insomnia) is not one of the most common reactions listed in regulatory documents. However, sleepiness or somnolence is classified as an uncommon side effect. This means it may occur in approximately 1% or less of patients.


Q: Does Zamur need to be taken indefinitely, or is it for short-term use?

According to official product information, Zamur is generally prescribed for short durations. Treatment is typically given for 5 to 10 days for acute bacterial infections, though the specific length of therapy depends on the condition being treated.


Q: What kind of studies have been conducted on Zamur's long-term use?

Research has included treatment durations up to 20 days for certain conditions like early Lyme disease. However, regulatory text indicates that evidence remains limited for very long-term outcomes, meaning effects tracked over periods longer than one year are not fully established.


Q: Is Zamur a controlled substance or does it have potential for dependence?

Zamur (Cefuroxime) is classified as a prescription-only medicine. Regulatory and drug enforcement agencies do not list it as a controlled substance, and it is not associated with potential for dependence.


Q: Can Zamur be used by people who are 65 or older?

The medicine has been studied in the elderly population. Regulatory reviews note that a dosage adjustment is generally not necessary based solely on age. However, regulatory documentation indicates that monitoring and potential dose adjustment may be required if the patient has impaired kidney function, which affects drug clearance.


Q: Why is Zamur typically prescribed over other options?

One pharmacological feature defined in official documents is the medicine’s enhanced stability against many beta-lactamase enzymes. This stability is a key factor that helps the drug work against certain bacterial strains that may be resistant to some other antibiotics.


Q: Does taking Zamur affect blood test results?

Yes, regulatory warnings note that the medicine can cause a positive Coombs' test, which is a type of blood test. It may also lead to false-positive results in certain urine tests for glucose (sugar).


Q: How long does Zamur stay in the body after the last use?

For people with normal kidney function, the drug's elimination half-life is approximately 75 to 90 minutes, and it is primarily excreted unchanged in the urine.


Q: Can Zamur cause changes in mood or make a person feel irritable?

While not common, official reports indicate that irritability has been listed as a less frequent side effect in post-marketing reports. This can sometimes occur alongside other nervous system disturbances.


Q: Are there special considerations for taking Zamur during warm weather or travel?

Official storage instructions require the medicine to be protected from excess heat and should be stored at a Controlled Room Temperature (typically 20°C to 25°C) to maintain stability. The medicine must also be protected from freezing.


Q: Can children or teenagers use Zamur under certain circumstances?

Official use is not established in infants younger than 3 months for the oral suspension. However, dosing information and usage guidelines are available for older children and adolescents for approved bacterial infections.


Q: What percentage of people report experiencing the mild side effects of Zamur?

Official adverse reaction reporting uses frequency classifications. The most common adverse reactions listed, such as diarrhea, headache, and dizziness, are reported to occur in ge 1/100 to <1/10 patients. This translates to an occurrence in 1% to 10% of patients.


Q: Are there any known long-term risks associated with Zamur use?

While the medicine is for short-term use, known risks associated with antibiotic treatment include the potential for the overgrowth of non-susceptible organisms. Official safety notes also mention the risk of Clostridioides difficile-associated diarrhea (CDAD), which can occur up to two months after stopping treatment.


Q: How long does the primary effect of Zamur usually last?

The medicine has a plasma half-life of about 75 to 90 minutes, and is eliminated primarily by the kidneys. It is typically dosed twice daily (every 12 hours) to ensure that consistent, adequate levels are maintained in the body to fight the infection.


Q: Can Zamur cause a metallic taste or dry mouth?

Official adverse reaction sections list dry mouth as an infrequent or less common side effect reported in post-marketing experience. Metallic taste is generally not listed as a side effect in regulatory documents.


Q: Is it possible to become resistant to the effects of Zamur over time?

The official safety notes highlight the risk of the overgrowth of non-susceptible organisms and the development of antibiotic-resistant bacteria. This is a potential risk associated with the use of most antibiotics.


Q: Can Zamur be taken at any time of day, or is a specific time recommended?

The oral form is typically prescribed to be taken twice daily, which means approximately every 12 hours. Regulatory documents note that taking it at the same time every day is suggested to help maintain consistent drug levels in the body.


Q: Is Zamur used to manage acute issues or chronic conditions?

Official documents describe Zamur as being used for the treatment of acute bacterial infections and it is prescribed for short durations (typically 5 to 10 days). It is not listed for managing long-term chronic diseases.


Q: Why are there different dosing options mentioned for Zamur in the labeling?

Official labeling specifies that doses are adjusted based on several clinical factors. These factors include the type and severity of the infection being treated, the chosen route of administration (oral vs. injection), and patient factors like age, weight, and kidney function.


Q: What should be avoided during the initial week of using Zamur?

Official interaction and administration rules state that gastric acidity reducers (like antacids) should be avoided close to the oral dose. To prevent reduced absorption, antacids must be separated by at least one hour before or two hours after taking Zamur.

How should Zamur be stored and disposed of?

How to Store and Dispose of Zamur

Zamur (Cefuroxime Axetil) must be stored and handled according to specific regulatory requirements to maintain product stability and ensure household safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, typically 20, C to 25, C (68, F to 77, F). Do not store above 30, C.
Protection Store in the original, tightly closed container and protect from excess heat, moisture, and freezing.
Safety The medication must be kept out of the sight and reach of children and secured with a locked safety cap if available.

Disposal Instructions

Unused or expired Zamur should not be disposed of in household waste or flushed down the toilet. Disposal must comply with local regulations for pharmaceutical waste. Consult a pharmacist or healthcare professional for instructions on safe disposal or how to access a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zamur found in:

A-Z Index: